Alligator Bioscience Dividendos y recompras

Dividendo controles de criterios 0/6

Alligator Bioscience no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-24.2%

Rendimiento de la recompra

Rendimiento total para el accionista	-24.2%
Rendimiento futuro de los dividendos	0%
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ATORX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ATORX han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Alligator Bioscience vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de ATORX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (ATORX)	n/a
Suelo de mercado 25% (SE)	1.6%
Techo de mercado 25% (SE)	4.8%
Media de la industria (Biotechs)	1.6%
Analista de previsiones (ATORX) (hasta 3 años)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ATORX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ATORX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de ATORX para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ATORX no ha comunicado ningún pago.

Alligator Bioscience Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Consensus revenue estimates fall by 17%

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Third quarter 2024 earnings released: kr0.08 loss per share (vs kr0.083 loss in 3Q 2023)

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Price target increased by 18% to kr2.23

Consensus revenue estimates decrease by 31%

Second quarter 2024 earnings released: kr0.066 loss per share (vs kr0.19 loss in 2Q 2023)

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Consensus EPS estimates upgraded to kr0.46 loss, revenue downgraded

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

High number of new directors

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

New minor risk - Share price stability

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

New minor risk - Profitability

Third quarter 2023 earnings released

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Price target decreased by 19% to kr1.90

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Consensus revenue estimates increase by 11%

Price target decreased by 36% to kr2.33

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

High number of new directors

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.43 loss in 3Q 2021)

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: kr0.21 (vs kr0.41 loss in 2Q 2021)

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Vice Chairman of the Board recently bought kr152k worth of stock

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Consensus forecasts updated

Chief Executive Officer recently bought kr51k worth of stock

Price target decreased to kr2.80

Less than half of directors are independent

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Consensus revenue estimates increase by 255%

Alligator Bioscience AB (publ) to Report Q3, 2022 Results on Oct 20, 2022

Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer

Alligator Bioscience Announces Optimize-1 Trial Update

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: kr0.43 loss per share (vs kr0.43 loss in 3Q 2020)

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Consensus revenue estimates increase to kr5.00m

Alligator Bioscience AB (Publ) Initiates A Phase II Trial with Mitazalimab, and Drug Candidate Ator-1017 Is Soon to Follow